William Wilson Net Worth

William Wilson biography

William R. Wilson serves as Independent Director of the Company. Since January 2006, he has served as Chairman, President and Chief Executive Officer of Wilson Land & Cattle Co., an investment company. Mr. Wilson has more than 40 years of legal experience in health care regulation, biotechnology, clinical trial management, nursing home licensing and regulation, physician accreditation, securities, corporate governance, contractual and other legal matters. Mr. Wilson is a member of the State Bar of Texas and has been admitted to practice before the United States District Court for the Western District of Texas. Mr. Wilson previously served as Judge of the 250th District Court of Travis County, Texas, where he presided over civil litigation, and as Assistant District Attorney for Dallas County, Texas. Mr. Wilson holds a Bachelor of Science degree from Vanderbilt University and a JD degree from Southern Methodist University.

How old is William Wilson?

William Wilson is 70, he's been the Independent Director of Genprex Inc since 2020. There are no older and 12 younger executives at Genprex Inc.

What's William Wilson's mailing address?

William's mailing address filed with the SEC is 3300 BEE CAVE ROAD, #650-227, AUSTIN, TX, 78746.

Insiders trading at Genprex Inc

Over the last 7 years, insiders at Genprex Inc have traded over $0 worth of Genprex Inc stock and bought 156,300 units worth $607,092 . The most active insiders traders include Ryan M. Confer, Christy M. Nance oraz Jack A Roth. On average, Genprex Inc executives and independent directors trade stock every 205 days with the average trade being worth of $14,575. The most recent stock trade was executed by John Rodney Varner on 21 April 2023, trading 19,000 units of GNPX stock currently worth $20,140.

What does Genprex Inc do?

genprex is mapping the future of cancer care. genprex's mission is to address the unmet medical needs of a growing population of cancer patients worldwide, through the development of a novel class of cancer drugs: immunogene therapy. our revolutionary clinical-stage products work synergistically with other approved and pipeline drugs to expand clinical indications for various cancers. about oncoprex® and lung cancer lung cancer is the second most common cancer in the u.s. but the leading cause of cancer death. there are approximately 225,000 new lung cancer cases in the u.s. per year and 1.8 million worldwide. the 5-year survival rate of stage iv non-small cell lung cancer (nsclc) is less than 1%, and treatment options beyond chemotherapy are lacking. approved nsclc targeted treatment options outside of chemo/radiation therapies only benefit a minority of patients. oncoprex® may now fill that gap by offering a targeted treatment option for a majority of nsclc patients. oncoprex® is cur

Genprex Inc executives and stock owners

Genprex Inc executives and other stock owners filed with the SEC include:

• Ryan Confer,
  Chief Financial Officer
• John Rodney Varner,
  Co, Founder, Pres, CEO, Sec. & Chairman
• J. Rodney Varner,
  Chairman of the Board, President, Chief Executive Officer, Secretary
• Catherine M. Vaczy,
  Exec. VP, Gen. Counsel & Chief Strategy Officer
• Catherine M. Vaczy Esq.,
  Exec. VP, Gen. Counsel, Corp. Sec. & Chief Strategy Officer
• Ryan M. Confer M.S.,
  Chief Financial Officer
• William Wilson,
  Independent Director
• Jose Moreno Toscano,
  Independent Director
• Brent Longnecker,
  Independent Director
• Catherine Vaczy,
  Executive Vice President, Chief Strategy Officer
• Michael Redman,
  Chief Operating Officer, Executive Vice President
• David M. Schloss,
  Sr. VP of HR
• Greg Jancarik C.M.A., CPA, M.B.A.,
  Corp. Controller
• Dr. Mark S. Berger M.D.,
  Chief Medical Officer
• Dr. Hemant Kumar C.P.M., EMBA, Ph.D.,
  Chief Manufacturing & Technology Officer
• Dr. Jack A. Roth F.A.C.S., FACS, M.D.,
  Chairman of Scientific & Medical Advisory Board
• Dr. William E. Gannon Jr.,
  Member of Clinical Advisory Board & VP of Regulatory Affairs
• Thomas C. Gallagher Esq.,
  Sr. VP of Intellectual Property & Licensing
• Kalyn Dabbs,
  Sr. Mang. of Communications & Marketing
• Christy M. Nance,
  10% owner
• Jack A Roth,
  10% owner
• Viet An Hoan Ly,
  10% owner
• Inc. Genprex,,
  Chief Executive Officer
• Robert W. Pearson,
  Director
• David E. Friedman,
  Director
• Julien L Pham,
  President & COO
• Mark Stanley Berger,
  Chief Medical Officer
• Hermant Kumar,
  Chief Mfgr & Tech Officer